Literature DB >> 1825854

Measles virus nucleocapsid protein protects rats from encephalitis.

B Bankamp1, U G Brinckmann, A Reich, S Niewiesk, V ter Meulen, U G Liebert.   

Abstract

Lewis rats immunized with recombinant vaccinia virus expressing the nucleocapsid (N) protein of measles virus were protected from encephalitis when subsequently challenged by intracerebral infection with neurotropic measles virus. Immunized rats revealed polyvalent antibodies to the N protein of measles virus in the absence of any neutralizing antibodies as well as an N protein-specific proliferative lymphocyte response. Depletion of CD8+ T lymphocytes did not abrogate the protective potential of the N protein-specific cell-mediated immune response in rats, while protection could be adoptively transferred with N protein-specific CD4+ T lymphocytes. These results indicate that a CD4+ cell-mediated immune response specific for the N protein of measles virus is sufficient to control measles virus infections of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825854      PMCID: PMC239973     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

Review 1.  The regulation and expression of MHC class I genes.

Authors:  B David-Watine; A Israël; P Kourilsky
Journal:  Immunol Today       Date:  1990-08

2.  Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase.

Authors:  M Del Val; K Münch; M J Reddehase; U H Koszinowski
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

Review 3.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.

Authors:  M Hany; S Oehen; M Schulz; H Hengartner; M Mackett; D H Bishop; H Overton; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1989-03       Impact factor: 5.532

5.  Long-term depletion of CD8+ T cells in vivo in the rat: no observed role for CD8+ (cytotoxic/suppressor) cells in the immunoregulation of experimental allergic encephalomyelitis.

Authors:  J D Sedgwick
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

6.  Antibody-mediated cytotoxicity after measles virus infection.

Authors:  R Kibler; V T Meulen
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

7.  Humoral immune response in dogs with old dog encephalitis and chromic distemper meningo-encephalitis.

Authors:  B K Rima; K Baczko; D T Imagawa; V ter Meulen
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

8.  Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.

Authors:  M K Spriggs; P L Collins; E Tierney; W T London; B R Murphy
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes.

Authors:  F Gotch; A McMichael; G Smith; B Moss
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

10.  Induction of autoimmune reactions to myelin basic protein in measles virus encephalitis in Lewis rats.

Authors:  U G Liebert; C Linington; V ter Meulen
Journal:  J Neuroimmunol       Date:  1988-01       Impact factor: 3.478

View more
  22 in total

Review 1.  Negative signaling in health and disease.

Authors:  K M Coggeshall
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

Authors:  C D Partidos; P Vohra; M W Steward
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Assembly of nucleocapsidlike structures in animal cells infected with a vaccinia virus recombinant encoding the measles virus nucleoprotein.

Authors:  D Spehner; A Kirn; R Drillien
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

Authors:  F Bouche; W Ammerlaan; F Berthet; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

5.  Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.

Authors:  Tanner S Miest; Koon-Chu Yaiw; Marie Frenzke; Johanna Lampe; Andrew W Hudacek; Christoph Springfeld; Veronika von Messling; Guy Ungerechts; Roberto Cattaneo
Journal:  Mol Ther       Date:  2011-05-24       Impact factor: 11.454

6.  Effect of immune priming on Borna disease.

Authors:  A J Lewis; J L Whitton; C G Hatalski; H Weissenböck; W I Lipkin
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  CD4+ T cells control measles virus infection of the central nervous system.

Authors:  A Reich; O Erlwein; S Niewiesk; V ter Meulen; U G Liebert
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

8.  Borna disease: association with a maturation defect in the cellular immune response.

Authors:  K M Carbone; S W Park; S A Rubin; R W Waltrip; G B Vogelsang
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Susceptibility to measles virus-induced encephalitis in mice correlates with impaired antigen presentation to cytotoxic T lymphocytes.

Authors:  S Niewiesk; U Brinckmann; B Bankamp; S Sirak; U G Liebert; V ter Meulen
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays.

Authors:  K B Hummel; D D Erdman; J Heath; W J Bellini
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.